Ruxolitinib cream ameliorated dermatitis symptoms by modulating the transcription of genes directly involved in TSLP signaling, such as IL-7 receptor (Il7r) and JAK-STATs (37–39). The gene discussed is TSLP; the disease is skin disorder.